Business Wire - September 27, 2006
"The Apollo study advances our mission to establish the industry for medical devices to treat infectious disease," stated Aethlon Chairman & CEO James A. Joyce. "The study also triggers our regulatory endeavors in the United States and sets the stage for us to expand efforts to treat multiple disease targets in India," concluded Joyce.
The report details clinical data collected during a study sponsored by Aethlon Medical to demonstrate the safety of the Hemopurifier(TM) in health-compromised humans. The study also provided an opportunity to observe the capture of Hepatitis-C virus ("HCV") from HCV infected end stage renal disease ("ESRD") study subjects undergoing intermittent dialysis. In tested cartridges, up to 52% of pre-treatment viral load was captured during a single treatment with the Hemopurifier(TM). Twenty-four Hemopurifier cartridges were tested on four study subjects suffering from ESRD and HCV infection. Each cartridge purified the blood of study subjects for up to four hours in six sequential treatments per patient every two to three days. All enrolled patients completed the entire treatment regimen.
About Aethlon Medical
Aethlon Medical is developing the first-in-class medical device to treat infectious disease. The device, known as the Hemopurifier(TM), is a broad-spectrum treatment countermeasure against drug and vaccine resistant bioweapons, naturally evolving pandemic threats such as H5N1 Avian Flu, and chronic infectious disease targets, including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). Global researcher Frost & Sullivan recently awarded the Hemopurifier(TM) the 2006 Technology Innovation Award for its advances in the field of biodefense. Aethlon has also initiated research on a second generation Hemopurifier(TM) that targets the capture of growth factors inherent in the spread of Cancer. More information on Aethlon Medical and the Hemopurifier(TM) technology can be found at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
CONTACT: Aethlon Medical, Inc.
Jeff Richardson, 858-459-7800, x302
jrichardson@aethlonmedical.com
SOURCE: Aethlon Medical, Inc.
060927
BW060914
Copyright © 2006 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .